Data Support Intermittent ADT for Metastatic PCa

Authors: RUN

Intermittent androgen deprivation therapy (ADT) may be as safe as continuous ADT in the treatment of metastatic prostate cancer (PCa), researchers concluded.

In a study of 383 men with metastatic PCa, Nicolas Mottet, MD, of the Clinique Mutualiste de la Loire, Saint-Etienne, France, and colleagues observed no statistical difference in either overall or progression-free survival between the two treatment strategies, according to an online report in BJU International. They concluded that intermittent ADT “could be an option in highly responding and well-informed metastatic patients even if no clear benefit in health-related quality of life was shown.”

Dr. Mottet's team added that intermittent ADT may be of interest to patients with metastatic PCa who experience significant treatment-induced side effects.

Of the 383 patients, 173 had a PSA level below 4 ng/mL after six months of induction of ADT. The investigators randomized subjects to receive either continuous or intermittent ADT. Median overall survival was 52 and 42 months, respectively, and median progression-free survival was 15.1 and 20.7 months, respectively. The differences between treatment arms were not statistically significant.

The researchers observed significantly fewer treatment-emergent adverse events in the intermittent group, which also had a lower incidence of headache and hot flushes.

Read more

PUA Social Network

Twitter Facebook

Contact us

The Philippine Urological Association,Inc
3rd floor. PCS Bldg., 992 EDSA, Quezon City,
Metro Manila, PHILIPPINES 1105
View Map


eMail us